When EMA and FDA decisions conflict: differences in patients or in regulation?

@article{Wolfe2013WhenEA,
  title={When EMA and FDA decisions conflict: differences in patients or in regulation?},
  author={S. Wolfe},
  journal={BMJ : British Medical Journal},
  year={2013},
  volume={347}
}
  • S. Wolfe
  • Published 2013
  • Medicine
  • BMJ : British Medical Journal
  • In his new regular column Sid Wolfe asks why the two regulatory bodies have arrived at different decisions on the same diet drugs 
    13 Citations
    Illicit Internet availability of drugs subject to recall and patient safety consequences
    • 13
    Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles
    • 83
    Horizons in the Pharmacotherapy of Obesity
    • 11
    • PDF
    Medications for the treatment of obesity in adolescents
    Current Perspectives on Long-term Obesity Pharmacotherapy.
    • S. Wharton
    • Medicine
    • Canadian journal of diabetes
    • 2016
    • 15
    Capsaicinoids : a potential role for weight management
    • PDF
    Pharmacotherapy for weight loss
    • 8

    References

    SHOWING 1-10 OF 12 REFERENCES
    Withdrawal of sibutramine in Europe
    • 64
    European regulatory body recommends suspension of rosiglitazone
    • D. Cohen
    • Medicine
    • BMJ : British Medical Journal
    • 2010
    • 8
    Elevated heart rate: a "new" cardiovascular risk factor?
    • P. Palatini
    • Medicine
    • Progress in cardiovascular diseases
    • 2009
    • 81
    FDA approves Belviq to treat some overweight or obese adults.
    • Medicine
    • Home healthcare nurse
    • 2012
    • 32
    22529: lorcaserin hydrochloride tablets, 10 mg [FDA briefing document for 10 May 2012 advisory committee meeting
      Advisory Committee meeting for phentermine/topiramate (Qnexa) [briefing memo
        Application number 022529Orig1s000: approval letter
          Clinical briefing document: Endocrinologic and Metabolic Drugs Advisory Committee meeting
            FDA approves weight-management drug Qsymia
              Medications target long-term weight control